Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 4/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459586 | 0.80 | TNKS (0.31) | TNKS | |
| SCHEMBL23459368 | 0.80 | TNKS (0.31) | TNKS | |
| SCHEMBL23459367 | 0.80 | TNKS (0.31) | TNKS | |
| SCHEMBL23460556 | 0.79 | TNKS (0.33) | CDK4TNKS | |
| SCHEMBL735829 | 0.79 | FASN (0.39) | HRH3HSD11B1POLBGAAALDH1A1 | |
| SCHEMBL23460060 | 0.78 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL25041326 | 0.77 | TNKS (0.32) | TNKS | |
| SCHEMBL29993201 | 0.77 | TNKS (0.32) | TNKS | |
| SCHEMBL23481178 | 0.77 | TNKS (0.32) | TNKS | |
| SCHEMBL736458 | 0.77 | FASN (0.39) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021113363-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | HRH3 2916/4885CDK4 153/4885HSD11B1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.